GENFIT to Host Virtual KOL Event Focused on MASH Diagnostics on September 9, 2026

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), September 3, 2026 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that it will host a virtual key opinion leader (KOL) event on Wednesday, September 9, 2026 at 10:00 AM ET. The event will highlight the evolving landscape of diagnostic testing for Metabolic dysfunction-Associated SteatoHepatitis (MASH) and will feature Dr. Vlad Ratziu, MD, PhD (Sorbonne University, Pitié-Salpêtrière Hospital, Institute for Cardiometabolism and Nutrition, Paris). To register, click here.